Antidepressant use and body mass index change in overweight adolescents: A historical cohort study

Innovations in Clinical Neuroscience

Volumn 11, Issue 11-12, 2014, Pages 14-21

  Cockerill, Richard G ^a   Biggs, Bridget K ^b   Oesterle, Tyler S ^b   Croarkin, Paul E ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Adolescent; Antidepressant; Depression; Obesity; SSRI

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ARTICLE; BODY MASS; DEPRESSION; ETHNICITY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBESITY;

EID: 84938081312     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication—Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49(10):980–989. Epub 2010 Jul 31
2. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA. 2012;307(5):483–490. Epub 2012 Jan 17
3. Phillips BA, Gaudette S, McCracken A, et al. Psychosocial functioning in children and adolescents with extreme obesity. J Clin Psychol Med Settings. 2012;19(3):277–284
4. Gracious BL, Cook SR, Meyer AE, Chirieac MC, Malhi N, Fischetti AT, et al. Prevalence of overweight and obesity in adolescents with severe mental illness: a cross-sectional chart review. J Clin Psychiatry. 2010 Jul;71(7):949–54. Epub 2010 May 4
5. Anderson SE, Cohen P, Naumova EN, Must A. Association of depression and anxiety disorders with weight change in a prospective community-based study of children followed up into adulthood. Arch Pediatr Adolesc Med. 2006;160(3):285–291
6. Goodman E, Whitaker RC. A prospective study of the role of depression in the development and persistence of adolescent obesity. Pediatrics. 2002;110(3):497–504
7. Pine DS, Goldstein RB, Wolk S, Weissman MM. The association between childhood depression and adulthood body mass index. Pediatrics. 2001;107(5):1049–1056
8. Mustillo S, Worthman C, Erkanli A, et al. Obesity and psychiatric disorder: developmental trajectories. Pediatrics. 2003;111(4 Pt 1):851–859
9. Goodman E, Must A. Depressive symptoms in severely obese compared with normal weight adolescents: results from a community-based longitudinal study. J Adolesc Health. 2011;49(1):64–69.Epub 2011 Mar 12
10. Erickson SJ, Robinson TN, Haydel KF, Killen JD. Are overweight children unhappy? Body mass index, depressive symptoms, and overweight concerns in elementary school children. Arch Pediatr Adolesc Med. 2000;154(9):931–935
11. Britz B, Siegfried W, Ziegler A, et al. Rates of psychiatric disorders in a clinical study group of adolescents with extreme obesity and in obese adolescents ascertained via a population based study. Int J Obes Relat Metab Disord. 2000;24(12):1707–1714
12. Friedman MA, Wilfley DE, Pike KM, et al. The relationship between weight and psychological functioning among adolescent girls. Obes Res. 1995;3(1):57–62
13. Lamertz CM, Jacobi C, Yassouridis A, et al. Are obese adolescents and young adults at higher risk for mental disorders?: a community survey. Obes Res. 2002;10(11):1152–1160
14. Wardle J, Williamson S, Johnson F, Edwards C. Depression in adolescent obesity: cultural moderators of the association between obesity and depressive symptoms. Int J Obes (Lond). 2006;30(4):634–643
15. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and metaanalysis. J Clin Psychiatry. 2010;71(10):1259–1272
16. Schwartz TL, Nihalani N, Jindal S, et al. Psychiatric medication-induced obesity: a review. Obes Rev. 2004;5(2):115–121
17. Ribeiro L, Busnello JV, Kauer- Sant’Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001;34(10):1303–1307
18. Leinonen E, Skarstein J, Behnke K, et al, Nordic Antidepressant Study Group. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol. 1999;14(6):329–337
19. Andershon F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and risk of diabetes mellitus. Am J Psychiatry. 2009;166(5):591–598
20. Jerrell JM, Tripathi A, Rizvi AA, McIntyre RS. The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis. Prim Care Companion CNS Disord. 2012;14(1).
21. Khoza S, Barner JC, Bohman TMS, et al. Use of antidepressant agents and the risk of type 2 diabetes. Eur J Clin Pharmacol. 2012;68(9):1295–1302
22. Levine MD, Perkins KA, Kalarchian MA, et al. Bupropion and cognitive behavioral therapy for weightconcerned women smokers. Arch Intern Med. 2010;170(6):543–550
23. Gadde KM, Zhang W, Foust MS. Bupropion treatment of olanzapineassociated weight gain: an openlabel, prospective trial. J Clin Psychopharmacol. 2006;26(4):409–413
24. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–120. Epub 2010 Jun 17
25. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of irtazapine. CNS Drug Rev. 2001;7(3):249–264
26. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60 Suppl 4:4–11
27. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–526
28. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–1773. Erratum in: JAMA. 2009;302(21):2322
29. Plodkowski RA, Nguyen Q, Sundaram U, et al. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother. 2001;10(6):1069–1081
30. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005–2008 [internet]. Number 76, October 2011. Atlanta (GA): Center for Disease Control and Prevention. http://www.cdc.gov/nchs/data/databriefs/db76.htm. Accessed December 18, 2014
31. Jerrell JM. Neuroendocrine-related adverse events associated with antidepressant treatment in children and adolescents. CNS Neurosci Ther. 2010;16(2):83–90. Epub 2009 Sep 21
32. Disclosure of health records for external research. Minn Rev Stat. § 144.295 (2012).
33. Barlow SE, Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120 Suppl 4:S164–92
34. Download and register G*Power 3 [Internet]. Dusseldorf (Germany): Heinrich Heine Universitat Dusseldorf [German]. http://www.psycho.uniduesseldorf.de/abteilungen/aap/gpow er3/download-and-register. Accessed December 18, 2014
35. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9(9):544–551
36. A SAS program for the CDC growth charts [internet]. Atlanta (GA): Centers for Disease Control and Prevention. January 13, 2014 http://www.cdc.gov/nccdphp/dnpao/g rowthcharts/resources/sas.htm. Accessed December 18, 2014
37. Hankin BL, Abramson LY, Moffitt TE, et al. Development of depression from preadolescence to young adulthood: emerging gender differences in a 10-year longitudinal study. J Abnorm Psychol. 1998;107(1):128–140
38. Schwartz TL, Nihalani N, Virk S, et al. Psychiatric medication-induced obesity: treatment options. Obes Rev. 2004;5(4):233–238
39. Birmaher B, Brent D, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1503–1526
40. Pfalzgraf AR, Scott V, Makela E, et al. Child psychiatrists’ self-reported treatment and monitoring of children and adolescents with major depressive disorder. J Psychiatr Pract. 2012;18(4):253–261
41. Taveras EM, Gillman MW, Kleinman KP, et al. Reducing racial/ethnic disparities in childhood obesity: the role of early life risk factors. JAMA Pediatr. 2013;167(8):731–738
42. Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry. 2011;72(5):655–670
43. Sakolsky D, Birmaher B. Developmentally informed pharmacotherapy for child and adolescent depressive disorders. Child Adolesc Psychiatr Clin N Am. 2012;21(2):313–25. Epub 2012 Feb 24
44. Skinner AC, Steiner MJ, Henderson FW, Perrin EM. Multiple markers of inflammation and weight status: cross-sectional analyses throughout childhood. Pediatrics. 2010;125(4):e801–9.Epub 2010 Mar 1
45. Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012;12:CD009138.